PAVM
PAVmed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 4
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Negative Gross Margin
Significant Net Income Decline
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PAVM
Pavmed Inc.
A commercial-stage medical technology company that focused on the medical device, diagnostics, and digital health sectors
Healthcare Equipment and Supplies
06/26/2014
07/27/2016
NASDAQ Stock Exchange
39
12-31
Common stock
360 Madison Avenue , 25th Floor , New York, NY 10017
--
PAVmed Inc., was incorporated on June 26, 2014. The company is a medical device company that aims to conceive, develop and commercialize a diverse pipeline of innovative products that the company believes meet unmet clinical needs and have attractive market opportunities. The company's goal is to enhance and accelerate value creation by adopting a business model focused on capital and time efficiency. The company intends to continuously explore promising ideas and opportunities that meet the company's project selection criteria, not limited to any target profession or condition. A medical device company organized to conceive, develop and commercialize a diverse pipeline of innovative products that the company believes address unmet clinical needs and have attractive market opportunities. The company's goal is to enhance and accelerate value creation by adopting a business model focused on capital and time efficiency. The company intends to continuously explore promising ideas and opportunities that meet the company's project selection criteria, not limited to any target profession or condition.
Earnings Call
Q1/2025
Estimate EPS-0.29
Actual EPS0.34
Estimate Revenue10.00K
Actual Revenue8.00K
PAVmed's Q1 2025: Unraveling Contradictions in FDA Approval, OpEx, and Biopharma Expansion
May 21,2025 12:54
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.25
Actual EPS-0.74
Estimate Revenue10.00K
Actual Revenue6.00K
PAVmed's Q2 2025 Earnings Call: Unraveling Contradictions in Medicare Strategy, FDA Timelines, and Biopharma Expansion
Aug 13,2025 05:30
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PAVM has released its 2025 Q3 earnings. EPS was reported at -0.29, versus the expected -0.2, missing expectations. The chart below visualizes how PAVM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PAVM has released its 2025 Q3 earnings report, with revenue of 5.00K, reflecting a YoY change of -99.50%, and net profit of -6.01M, showing a YoY change of -109.90%. The Sankey diagram below clearly presents PAVM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
